Financial & SEC Reports
Here you will find a summary of Celldex Therapeutics, Inc.'s latest financial information.
Data provided by Kaleidoscope.
FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.
Investor Relations Contacts
Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration
Patrick Till
Senior Director
Investor Relations & Corporate Communications
More →
About us
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Our Pipeline
© 2021 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact